REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)

Status Authorised, recruitment pending

Countries 1

Sites 1

Immune Aging, Chronic inflammation

Sponsor: Radboud universitair medisch centrum Stichting
Participant type: Healthy volunteers
Age range: 18-64 years, 65+ years
Gender: Male and Female
Therapeutic area: Diseases [C] - Immune System Diseases [C20], Phenomena and Processes [G] - Immune system processes [G12]
Decision date (initial): 2026-06-08
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

CTIS Part I — objectives, methods, condition coding

Immune Aging, Chronic inflammation

Version	Level	Code	Term	System organ class
28.0	SOC	10021428	Immune system disorders	4
20.0	LLT	10013229	Disorder immune system (NOS)	10021428
20.0	PT	10021425	Immune system disorder	100000004870

Sponsor organisations, regulatory contacts, third parties

1 EU/EEA country · 1 investigational sites

Country	MS status	Planned subjects	Sites
Spain		0	1
Rest of world	—	0	—

1 site ·

Centro De Oftalmologia Barraquer S.A.

Internal Medicine, Infectious Diseases, Calle Muntaner 314, 08021, Barcelona

1 submissions — initial application plus substantial / non-substantial modifications

#	Type	Code	Submitted	Reference MS	Conclusion	Decision date
1	INITIAL	IN	2026-03-19	Netherlands	Acceptable 2026-06-08	2026-06-08